- Home
- RAMP vs BEAM Comparison
RAMP vs BEAM Comparison
Compare RAMP & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- BEAM
- Stock Information
- Founded
- RAMP 2018
- BEAM 2017
- Country
- RAMP United States
- BEAM United States
- Employees
- RAMP N/A
- BEAM N/A
- Industry
- RAMP EDP Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAMP Technology
- BEAM Health Care
- Exchange
- RAMP Nasdaq
- BEAM Nasdaq
- Market Cap
- RAMP 2.0B
- BEAM 1.9B
- IPO Year
- RAMP 1987
- BEAM 2020
- Fundamental
- Price
- RAMP $32.19
- BEAM $23.44
- Analyst Decision
- RAMP Buy
- BEAM Buy
- Analyst Count
- RAMP 7
- BEAM 10
- Target Price
- RAMP $39.71
- BEAM $47.67
- AVG Volume (30 Days)
- RAMP 499.0K
- BEAM 1.3M
- Earning Date
- RAMP 02-06-2025
- BEAM 02-25-2025
- Dividend Yield
- RAMP N/A
- BEAM N/A
- EPS Growth
- RAMP N/A
- BEAM N/A
- EPS
- RAMP 0.04
- BEAM N/A
- Revenue
- RAMP $707,165,000.00
- BEAM $349,643,000.00
- Revenue This Year
- RAMP $13.82
- BEAM N/A
- Revenue Next Year
- RAMP $9.09
- BEAM $10.82
- P/E Ratio
- RAMP $738.15
- BEAM N/A
- Revenue Growth
- RAMP 13.84
- BEAM 328.73
- 52 Week Low
- RAMP $21.45
- BEAM $20.84
- 52 Week High
- RAMP $42.10
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- RAMP 63.92
- BEAM 38.04
- Support Level
- RAMP $27.99
- BEAM $22.50
- Resistance Level
- RAMP $31.90
- BEAM $28.39
- Average True Range (ATR)
- RAMP 0.80
- BEAM 1.68
- MACD
- RAMP 0.11
- BEAM -0.41
- Stochastic Oscillator
- RAMP 89.94
- BEAM 15.05
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.